{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:52:46Z","timestamp":1790729566371,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.intimp.2022.109075","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T02:33:55Z","timestamp":1658284435000},"page":"109075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Current evidence on the use of anakinra in COVID-19"],"prefix":"10.1016","volume":"111","author":[{"given":"Elnaz","family":"Khani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Shahrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Pourkarim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Afsharirad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Solduzian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.109075_b0005","unstructured":"WHO Coronavirus (COVID-19) Dashboard, World Heal. Organ. (n.d.). https:\/\/covid19.who.int."},{"key":"10.1016\/j.intimp.2022.109075_b0010","unstructured":"Symptoms of COVID-19, 2021, Centers Dis. Control Prev. (n.d.). https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/symptoms-testing\/symptoms.html."},{"issue":"11","key":"10.1016\/j.intimp.2022.109075_b0015","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/17476348.2020.1804365","article-title":"Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis","volume":"14","author":"Hasan","year":"2020","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.intimp.2022.109075_b0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijid.2021.02.041","article-title":"Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: a single-centre retrospective comparative study","volume":"105","author":"de la Calle","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.109075_b0025","unstructured":"EMA recommends approval for use of Kineret in adults with COVID-19, Eur. Med. Agency. (n.d.)."},{"issue":"2","key":"10.1016\/j.intimp.2022.109075_b0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08830185.2021.1884248","article-title":"Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality","volume":"41","author":"Que","year":"2022","journal-title":"Int. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109075_b0035","first-page":"124","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis, Pediatr. Blood","volume":"48","author":"Henter","year":"2007","journal-title":"Cancer."},{"key":"10.1016\/j.intimp.2022.109075_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-017-0930-5","article-title":"Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis","volume":"15","author":"Kyriazopoulou","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.intimp.2022.109075_b0045","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2005-05-1980","article-title":"Severe imbalance of IL-18\/IL-18BP in patients with secondary hemophagocytic syndrome","volume":"106","author":"Mazodier","year":"2005","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.intimp.2022.109075_b0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2020.06.017","article-title":"Cytokine Storms: Understanding COVID-19","volume":"53","author":"Mangalmurti","year":"2020","journal-title":"Immunity."},{"issue":"6","key":"10.1016\/j.intimp.2022.109075_b0055","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1164\/rccm.202005-1583OC","article-title":"Characterization of the inflammatory response to severe COVID-19 Illness","volume":"202","author":"McElvaney","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2022.109075_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41232-019-0101-5","article-title":"The role of interleukin-1 in general pathology","volume":"39","author":"Kaneko","year":"2019","journal-title":"Inflamm. Regen."},{"issue":"2-3","key":"10.1016\/j.intimp.2022.109075_b0065","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0165-5728(92)90049-Q","article-title":"Interleukin-1\u03b2 induction of tumor necrosis factor-alpha gene expression in human astroglioma cells","volume":"36","author":"Bethea","year":"1992","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2022.109075_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"5-6","key":"10.1016\/j.intimp.2022.109075_b0075","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s12026-016-8873-z","article-title":"Inflammasomes and its importance in viral infections","volume":"64","author":"Shrivastava","year":"2016","journal-title":"Immunol. Res."},{"issue":"6","key":"10.1016\/j.intimp.2022.109075_b0080","first-page":"e358","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome, Lancet","volume":"2","author":"Mehta","year":"2020","journal-title":"Rheumatol."},{"key":"10.1016\/j.intimp.2022.109075_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2016.00467","article-title":"IL-1 inhibition in systemic juvenile idiopathic arthritis","volume":"7","author":"Giancane","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109075_b0090","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ijid.2020.05.026","article-title":"Use of anakinra in severe COVID-19: a case report","volume":"96","author":"Filocamo","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2022.109075_b0095","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s10557-020-07044-3","article-title":"Anakinra for the Treatment of COVID-19-Associated Pericarditis: a Case Report","volume":"34","author":"Karadeniz","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"12","key":"10.1016\/j.intimp.2022.109075_b0100","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/ccr3.3307","article-title":"Treatment of cytokine storm syndrome with IL-1 receptor antagonist anakinra in a patient with ARDS caused by COVID-19 infection: a case report","volume":"8","author":"Kaps","year":"2020","journal-title":"Clin. Case Reports."},{"key":"10.1016\/j.intimp.2022.109075_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bcr-2020-237525","article-title":"Cytokine storm and use of anakinra in a patient with COVID-19","volume":"13","author":"Nemchand","year":"2020","journal-title":"BMJ Case Rep."},{"issue":"5","key":"10.1016\/j.intimp.2022.109075_b0110","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/03009742.2020.1789734","article-title":"Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome","volume":"49","author":"Steinhardt","year":"2020","journal-title":"Scand. J. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109075_b0115","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cjco.2020.10.003","article-title":"Rapid Response to Cytokine Storm Inhibition Using Anakinra in a Patient With COVID-19 Myocarditis","volume":"3","author":"Trpkov","year":"2021","journal-title":"CJC Open."},{"issue":"1","key":"10.1016\/j.intimp.2022.109075_b0120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2020.05.002","article-title":"Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease","volume":"146","author":"Pontali","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109075_b0125","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/annrheumdis-2020-217706","article-title":"Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: Case series","volume":"79","author":"Aouba","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2022.109075_b0130","first-page":"1990","article-title":"Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: a Case Series, Arthritis","volume":"72","author":"Navarro\u2010Mill\u00e1n","year":"2020","journal-title":"Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109075_b0135","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2021.01.024","article-title":"Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia","volume":"147","author":"Pontali","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2022.109075_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-02902-w","article-title":"Clinical determinants for fatality of 44,672 patients with COVID-19","volume":"24","author":"Deng","year":"2020","journal-title":"Crit. Care."},{"issue":"7821","key":"10.1016\/j.intimp.2022.109075_b0145","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature."},{"issue":"4","key":"10.1016\/j.intimp.2022.109075_b0150","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/jcph.1822","article-title":"Potential COVID-19 Therapeutic Agents and Vaccines: an Evidence-Based Review","volume":"61","author":"Khani","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109075_b0155","first-page":"e586","article-title":"Anakinra for severe forms of COVID-19, Lancet","volume":"2","author":"Huet","year":"2020","journal-title":"Rheumatol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109075_b0160","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1006\/cyto.1996.0110","article-title":"Inhibition of IL-1 induced tissue factor (TF) synthesis and procoagulant activity (PCA) in purified human monocytes by IL-4, IL-10 and IL-13","volume":"8","author":"Osnes","year":"1996","journal-title":"Cytokine."},{"key":"10.1016\/j.intimp.2022.109075_b0165","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3390\/jcm8122072","article-title":"Interleukin-1\u03b2 Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor","volume":"8","author":"Liberale","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2022.109075_b0170","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijid.2020.11.149","article-title":"Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study","volume":"103","author":"Balkhair","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.109075_b0175","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cmi.2020.10.002","article-title":"Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors\u2019 response","volume":"27","author":"Fiolet","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.intimp.2022.109075_b0180","unstructured":"K. Ramanathan, D. Antognini, A. Combes, M. Paden, B. Zakhary, M. Ogino, G. Maclaren, D. Brodie, Interleukin-1blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation:, Lancet Rheumatol. 2 (2020) 19\u201321. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/ S2665-9913(20)30127-2."},{"key":"10.1016\/j.intimp.2022.109075_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.675678","article-title":"Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation","volume":"12","author":"Della-Torre","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109075_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.66125","article-title":"An open label trial of anakinra to prevent respiratory failure in covid-19","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"Elife."},{"key":"10.1016\/j.intimp.2022.109075_b0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13054-020-02897-4","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia","volume":"24","author":"Rovina","year":"2020","journal-title":"Crit. Care."},{"key":"10.1016\/j.intimp.2022.109075_b0200","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1681\/ASN.2020060829","article-title":"Soluble urokinase receptor (SuPAR) in COVID-19-Related AKI","volume":"31","author":"Azam","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109075_b0205","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/art.22416","article-title":"The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor \u03b1-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis","volume":"56","author":"Bleesing","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2022.109075_b0210","first-page":"19","volume":"9","year":"2020","journal-title":"Respir Med."},{"issue":"12","key":"10.1016\/j.intimp.2022.109075_b0215","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S2213-2600(21)00377-5","article-title":"Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial","volume":"9","author":"Declercq","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"10","key":"10.1016\/j.intimp.2022.109075_b0220","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.intimp.2022.109075_b0225","doi-asserted-by":"crossref","first-page":"100560","DOI":"10.1016\/j.xcrm.2022.100560","article-title":"Development and validation of SCOPE score: a clinical score to predict COVID-19 pneumonia progression to severe respiratory failure","volume":"3","author":"Giamarellos-Bourboulis","year":"2022","journal-title":"Cell Reports Med."},{"key":"10.1016\/j.intimp.2022.109075_b0230","unstructured":"Kineret Assessment Report, Eur. Med. Agency. (n.d.). https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/kineret-h-c-000363-ii-0086-epar-assessment-report-variation_en.pdf."},{"key":"10.1016\/j.intimp.2022.109075_b0235","first-page":"1","article-title":"Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series","volume":"4","author":"Clark","year":"2020","journal-title":"Rheumatol. Adv. Pract."},{"issue":"12","key":"10.1016\/j.intimp.2022.109075_b0240","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1007\/s00277-020-04160-w","article-title":"IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection","volume":"99","author":"Villegas","year":"2020","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109075_b0245","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chom.2020.05.007","article-title":"Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis","volume":"28","author":"Dimopoulos","year":"2020","journal-title":"Cell Host Microbe."},{"key":"10.1016\/j.intimp.2022.109075_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.570993","article-title":"Controlling cytokine storm is vital in COVID-19","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109075_b0255","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0009-9236(03)00094-8","article-title":"Pharmacokinetics of anakinra in subjects with different levels of renal function","volume":"74","author":"Yang","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2022.109075_b0260","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/cts.12622","article-title":"Pharmacokinetics of anakinra in subjects of heavier vs. lighter body weights","volume":"12","author":"Yang","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.intimp.2022.109075_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-03364-w","article-title":"Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study","volume":"24","author":"Kooistra","year":"2020","journal-title":"Crit. Care."},{"key":"10.1016\/j.intimp.2022.109075_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00055","article-title":"Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis","volume":"10","author":"Karakike","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109075_b0275","doi-asserted-by":"crossref","unstructured":"D. B. Shakoory, M.D., George Washington University, Washington, P. J.A. Carcillo, M.D., University of Pittsburgh Medical Center, Pittsburgh, A. W. W. Chatham, M.D., University of Alabama at Birmingham, Birmingham, D. R. L. Amdur, Ph.D., George Washington University, Washington, P. H. Zhao, Ph.D., Temple University, Philadelphia, C. C.A. Dinarello, M.D., University of Colorado Denver, Aurora, A. R.Q. Cron, M.D. Ph.D., and University of Alabama at Birmingham, Birmingham, R. S.M. Opal, M.D. Brown University, Providence, Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: Re-analysis of a prior Phase III trial, Crit. Care Med. 44 (2016) 275\u2013281. https:\/\/doi.org\/10.1097\/CCM.0000000000001402.Interleukin-1.","DOI":"10.1097\/CCM.0000000000001402"},{"key":"10.1016\/j.intimp.2022.109075_b0280","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.jaut.2020.102537","article-title":"High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients","volume":"115","author":"Iglesias-Juli\u00e1n","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2022.109075_b0285","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijid.2020.07.081","article-title":"Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab","volume":"99","author":"Langer-Gould","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2022.109075_b0290","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.4049\/jimmunol.2001126","article-title":"IL-1 Receptor antagonist anakinra in the treatment of COVID-19 acute respiratory distress syndrome: a retrospective, observational study","volume":"206","author":"Franzetti","year":"2021","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109075_b0295","first-page":"e000894","article-title":"Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): a narrative review and the viewpoint of the latin american society of pediatric intensive care (SLACIP) sepsis committee, BMJ paediatr","volume":"5","author":"Fern\u00e1ndez-Sarmiento","year":"2021","journal-title":"Open."},{"key":"10.1016\/j.intimp.2022.109075_b0300","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1542\/hpeds.2020-0123","article-title":"COVID-19 and kawasaki disease: novel virus and novel case","volume":"10","author":"Jones","year":"2020","journal-title":"Hosp. Pediatr."},{"key":"10.1016\/j.intimp.2022.109075_b0305","first-page":"81","article-title":"Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19","volume":"35","author":"Tanner","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.intimp.2022.109075_b0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fped.2020.624248","article-title":"Case Report: use of anakinra in multisystem inflammatory syndrome during COVID-19 pandemic","volume":"8","author":"Della Paolera","year":"2021","journal-title":"Front. Pediatr."},{"issue":"4","key":"10.1016\/j.intimp.2022.109075_b0315","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa2021756","article-title":"Multisystem inflammatory syndrome in children in new york state","volume":"383","author":"Dufort","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.109075_b0320","doi-asserted-by":"crossref","unstructured":"M. S, Refractory Multi-Inflammatory Syndrome in a Two Weeks Old Neonate with COVID-19 Treated Successfully with Intravenous Immunoglobulin, Steroids and Anakinra, Open Access J. Microbiol. Biotechnol. 5 (2020) 1\u20139. https:\/\/doi.org\/10.23880\/oajmb-16000176.","DOI":"10.23880\/OAJMB-16000176"},{"key":"10.1016\/j.intimp.2022.109075_b0325","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA - J. Am. Med. Assoc."},{"issue":"5","key":"10.1016\/j.intimp.2022.109075_b0330","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PCC.0000000000000078","article-title":"Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction\/macrophage activating syndrome in critically Ill children","volume":"15","author":"Rajasekaran","year":"2014","journal-title":"Pediatr. Crit. Care Med."},{"issue":"11","key":"10.1016\/j.intimp.2022.109075_b0335","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1136\/ard.2008.105833","article-title":"A patient\u2019s wish: anakinra in pregnancy","volume":"68","author":"Berger","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2022.109075_b0340","unstructured":"N.I, o, Health, Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, (2022)."},{"issue":"9","key":"10.1016\/j.intimp.2022.109075_b0345","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/03630242.2021.1981517","article-title":"Can Anakinra and corticosteroid treatment be an effective option in pregnant women with severe Covid-19?","volume":"61","author":"Karaka\u015f","year":"2021","journal-title":"Women Heal."},{"key":"10.1016\/j.intimp.2022.109075_b0350","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/rheumatology\/kex305","article-title":"International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors","volume":"56","author":"Youngstein","year":"2017","journal-title":"Rheumatology."},{"key":"10.1016\/j.intimp.2022.109075_b0355","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.ijid.2021.03.031","article-title":"The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: a prospective cohort study with multivariate analysis of factors affecting the antibody response","volume":"105","author":"Ba\u015faran","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.109075_b0360","unstructured":"World Health Organization. WHO COVID-19 Case definition, Accessed December 16 2020. (n.d.). https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2."},{"issue":"9","key":"10.1016\/j.intimp.2022.109075_b0365","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/17476348.2020.1778470","article-title":"Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2","volume":"14","author":"Robba","year":"2020","journal-title":"Expert Rev. Respir. Med."},{"issue":"3","key":"10.1016\/j.intimp.2022.109075_b0370","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.chom.2020.07.005","article-title":"Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe."},{"issue":"1","key":"10.1016\/j.intimp.2022.109075_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14712598.2022.2006631","article-title":"The role of anti-IL-1 treatment in MIS-C patients","volume":"22","author":"Mastrolia","year":"2022","journal-title":"Expert Opin. Biol. Ther."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922005598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922005598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:43:43Z","timestamp":1761587023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922005598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":75,"alternative-id":["S1567576922005598"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109075","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current evidence on the use of anakinra in COVID-19","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109075"}}